4792-71-6 Usage
Uses
Used in Pharmaceutical Industry:
5,7-Dichloro-1H-indole-2-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of novel drug candidates with improved therapeutic properties, such as enhanced potency, selectivity, and reduced side effects. 5,7-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID's versatility in chemical reactions enables the creation of a wide range of indole-based drug molecules for the treatment of various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 5,7-Dichloro-1H-indole-2-carboxylic acid serves as a crucial building block for the synthesis of various agrochemical products, including pesticides and herbicides. Its incorporation into these products can lead to the development of more effective and environmentally friendly solutions for crop protection and management.
Used in Medicinal Chemistry Research:
5,7-Dichloro-1H-indole-2-carboxylic acid is used as a subject of interest in medicinal chemistry research due to its potential biological activities. Its antifungal properties make it a promising candidate for the development of new antifungal agents to combat drug-resistant fungal infections. Additionally, its anti-inflammatory effects open up possibilities for the creation of novel therapeutic agents for the treatment of inflammatory diseases.
Used in the Synthesis of Functionalized Indole Derivatives:
5,7-Dichloro-1H-indole-2-carboxylic acid is used as a versatile starting material for the synthesis of diverse functionalized indole derivatives. Its unique structural features and reactivity enable chemists to modify and functionalize the molecule, leading to the development of new compounds with various applications in different fields, such as materials science, catalysis, and supramolecular chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 4792-71-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,7,9 and 2 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 4792-71:
(6*4)+(5*7)+(4*9)+(3*2)+(2*7)+(1*1)=116
116 % 10 = 6
So 4792-71-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H5Cl2NO2/c10-5-1-4-2-7(9(13)14)12-8(4)6(11)3-5/h1-3,12H,(H,13,14)
4792-71-6Relevant articles and documents
SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
-
Paragraph 00240; 00244, (2019/03/17)
Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
The first potent and selective non-imidazole human histamine H4 receptor antagonists
Jablonowski, Jill A.,Grice, Cheryl A.,Chai, Wenying,Dvorak, Curt A.,Venable, Jennifer D.,Kwok, Annette K.,Ly, Kiev S.,Wei, Jianmei,Baker, Sherry M.,Desai, Pragnya J.,Jiang, Wen,Wilson, Sandy J.,Thurmond, Robin L.,Karlsson, Lars,Edwards, James P.,Lovenberg, Timothy W.,Carruthers, Nicholas I.
, p. 3957 - 3960 (2007/10/03)
Following the discovery of the human histamine H4 receptor, a high throughput screen of our corporate compound collection identified compound 6 as a potential lead. Investigation of the SAR resulted in the discovery of novel compounds 10e and 10l, which are the first potent and selective histamine H4 receptor antagonists to be described.
Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
-
, (2008/06/13)
Processes and intermediates for preparing compounds of Formula (I).
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
-
, (2008/06/13)
PCT No. PCT/IB95/00442 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed Jun. 6, 1995 PCT Pub. No. WO96/39384 PCT Pub. Date Dec. 12, 1996Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.
